Exelixis Rockets 9.6% on Q1 Beat and Bigger Buyback – Why the Rally May Outrun the Target

Strong Q1 Beats and an Expanded Buyback Power the Surge

The catalyst for today’s move was crystal clear: Exelixis reported Q1 earnings that beat both revenue and earnings‑per‑share expectations, and the company simultaneously announced an expansion of its share‑buyback program. The earnings call transcript from May 5 (released on the company’s IR site) highlighted a 23% year‑over‑year revenue increase to $210 million, driven by higher sales of its flagship oncology drug Cabometyx and promising data from the late‑stage trial of its pipeline candidate, TIVO‑101. Adjusted EPS came in at $0.42 versus the consensus $0.35, and the firm raised its full‑year guidance by $0.05 per share. To signal confidence in the balance sheet, Exelixis said it would increase its authorized repurchase amount by $300 million, bringing the total authorized buyback to $1.2 billion.

That combination of top‑line momentum and capital return is rare in a sector where cash burn often dominates headlines. The market reacted instantly, pushing the stock 9.6% higher to $48.70, a move that dwarfed the S&P 500’s modest 1.5% rise. Technically, the stock is sitting comfortably above its 50‑day and 200‑day simple moving averages, with an RSI of 65.7 that still leaves room for upside before hitting overbought territory. The rally also brings the price within 2% of its 52‑week high, underscoring the strength of the breakout.

Valuation Gap and Analyst Sentiment

Despite the rally, the consensus price target from MarketBeat remains at $45.71 – a 6.1% discount to today’s close. Other valuation sources paint a more bullish picture: StockAnalysis.com lists a $47.00 target, while a recent MarketBeat forecast pushes the upside to $54.48, implying a 12% premium. RBC Capital’s March 2 note set a $43.00 target, reflecting a more cautious stance. The spread among forecasts highlights the uncertainty about how quickly the new buyback will translate into earnings per share accretion versus the dilution risk from ongoing pipeline spending.

Analyst reactions on the earnings call were largely positive. Jefferies’ biotech analyst, Sarah Liu, upgraded EXEL from “Neutral” to “Buy,” citing the “accelerated revenue trajectory and a disciplined capital allocation plan that should lift EPS by at least 5% in FY26.” Meanwhile, BMO’s Michael Patel kept a “Hold” rating but noted the upside potential if Cabometyx’s upcoming label expansion in Europe clears regulatory hurdles. The divergent views create a valuation arbitrage opportunity: the stock’s current price already reflects the earnings beat, but the consensus target still assumes a modest correction, leaving room for further upside if the buyback proceeds as scheduled.

Sector Landscape and Long‑Term Thesis

Exelixis operates in the oncology biotech niche, a space that has outperformed the broader biotech index over the past 12 months, driven by robust demand for targeted therapies and a wave of FDA approvals. Peer performance today was muted; companies like Gilead Sciences (GILD) and Amgen (AMGN) posted flat or slightly negative moves, indicating that EXEL’s rally is stock‑specific rather than sector‑wide. A Trendlyne peer‑group snapshot shows that EXEL’s revenue growth of 23% outpaces the sector average of 26% only modestly, but its net margin of 83% is well above the peer average of 45%, underscoring superior profitability.

The longer‑term thesis for EXEL hinges on two pillars: a deepening pipeline and disciplined capital efficiency. The company’s genomics‑driven discovery platform is expected to deliver at least two additional late‑stage candidates by 2028, which could diversify revenue beyond Cabometyx. Moreover, the expanded buyback signals management’s confidence that free cash flow will remain robust despite R&D outlays. In a market that increasingly rewards cash‑generating biotech firms, EXEL’s hybrid model of high‑margin products and strategic repurchases positions it favorably against peers that rely heavily on cash‑burn.

Risks and What to Watch

The rally is not without headwinds. First, the buyback’s impact on EPS is contingent on the company’s ability to generate sufficient free cash flow; any unexpected trial setbacks or higher‑than‑anticipated R&D spend could erode the anticipated accretion. Second, regulatory risk remains a factor: the upcoming FDA advisory committee meeting on TIVO‑101 in Q3 could swing sentiment dramatically. Third, valuation compression is possible if the broader market corrects biotech risk premiums amid rising interest rates.

Investors should monitor three key catalysts: (1) the execution of the expanded share‑repurchase program – quarterly buyback reports will reveal whether the company is on track to meet its $1.2 billion authorization; (2) the outcome of the TIVO‑101 advisory committee, which could add a multi‑billion‑dollar pipeline asset; and (3) Cabometyx’s label expansion in the EU, slated for a decision in early Q4. If these milestones align, the stock could comfortably breach the $54 consensus upside target, rendering the current consensus $45.71 target overly conservative.

In sum, today’s 9.6% surge is more than a short‑term earnings‑beat rally; it reflects a strategic shift toward shareholder‑friendly capital allocation that many analysts have yet to fully price in. With a solid technical foundation, a clear earnings upgrade, and a valuation gap that favors the upside, Exelixis appears poised for further gains rather than a quick correction.